Barclays’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.53M | Sell |
32,254
-217,734
| -87% | -$11.5M | ﹤0.01% | 2515 |
|
|
2025
Q4 | $13.1M | Sell |
249,988
-99,863
| -29% | -$5.98M | ﹤0.01% | 1497 |
|
|
2025
Q3 | $22.7M | Sell |
349,851
-30,772
| -8% | -$1.77M | ﹤0.01% | 1167 |
|
|
2025
Q2 | $18.5M | Buy |
380,623
+290,997
| +325% | +$11.3M | ﹤0.01% | 1179 |
|
|
2025
Q1 | $3.05M | Sell |
89,626
-12,432
| -12% | -$527K | ﹤0.01% | 2311 |
|
|
2024
Q4 | $4.02M | Sell |
102,058
-27,790
| -21% | -$1.31M | ﹤0.01% | 2359 |
|
|
2024
Q3 | $6.1M | Buy |
129,848
+64,228
| +98% | +$3.26M | ﹤0.01% | 1911 |
|
|
2024
Q2 | $3.54M | Sell |
65,620
-190,711
| -74% | -$11M | ﹤0.01% | 1747 |
|
|
2024
Q1 | $17.5M | Sell |
256,331
-56,634
| -18% | -$4.05M | 0.01% | 1061 |
|
|
2023
Q4 | $19.6M | Sell |
312,965
-197,867
| -39% | -$10.9M | 0.01% | 1058 |
|
|
2023
Q3 | $23.2M | Buy |
510,832
+137,629
| +37% | +$7.11M | 0.01% | 716 |
|
|
2023
Q2 | $21M | Buy |
373,203
+11,444
| +3% | +$649K | 0.01% | 713 |
|
|
2023
Q1 | $16.4M | Sell |
361,759
-27,918
| -7% | -$1.36M | 0.01% | 940 |
|
|
2022
Q4 | $15.8M | Buy |
389,677
+280,911
| +258% | +$14.9M | 0.01% | 998 |
|
|
2022
Q3 | $7.11M | Buy |
108,766
+87,117
| +402% | +$6.31M | 0.01% | 986 |
|
|
2022
Q2 | $1.32M | Buy |
21,649
+4,025
| +23% | +$237K | ﹤0.01% | 2150 |
|
|
2022
Q1 | $1.11M | Buy |
17,624
+3,453
| +24% | +$217K | ﹤0.01% | 2324 |
|
|
2021
Q4 | $1.07M | Sell |
14,171
-18,859
| -57% | -$1.65M | ﹤0.01% | 2783 |
|
|
2021
Q3 | $3.7M | Buy |
33,030
+12,006
| +57% | +$1.51M | ﹤0.01% | 1838 |
|
|
2021
Q2 | $3.4M | Buy |
21,024
+15,224
| +262% | +$1.85M | ﹤0.01% | 1829 |
|
|
2021
Q1 | $706K | Sell |
5,800
-13,947
| -71% | -$2.11M | ﹤0.01% | 2982 |
|
|
2020
Q4 | $3.02M | Buy |
19,747
+6,390
| +48% | +$755K | ﹤0.01% | 1921 |
|
|
2020
Q3 | $1.12M | Buy |
13,357
+13,246
| +11,933% | +$1.17M | ﹤0.01% | 2599 |
|
|
2020
Q2 | $8K | Sell |
111
-37
| -25% | -$2.16K | ﹤0.01% | 5350 |
|
|
2020
Q1 | $6K | Sell |
148
-5,161
| -97% | -$266K | ﹤0.01% | 5906 |
|
|
2019
Q4 | $324K | Sell |
5,309
-8,568
| -62% | -$468K | ﹤0.01% | 4649 |
|
|
2019
Q3 | $568K | Buy |
13,877
+4,151
| +43% | +$198K | ﹤0.01% | 4142 |
|
|
2019
Q2 | $459K | Sell |
9,726
-5,073
| -34% | -$203K | ﹤0.01% | 4388 |
|
|
2019
Q1 | $528K | Buy |
14,799
+9,920
| +203% | +$343K | ﹤0.01% | 4060 |
|
|
2018
Q4 | $139K | Sell |
4,879
-7,302
| -60% | -$254K | ﹤0.01% | 4828 |
|
|
2018
Q3 | $541K | Sell |
12,181
-4,590
| -27% | -$240K | ﹤0.01% | 4203 |
|
|
2018
Q2 | $985K | Buy |
16,771
+1,071
| +7% | +$61K | ﹤0.01% | 3312 |
|
|
2018
Q1 | $717K | Buy |
15,700
+400
| +3% | +$16.5K | ﹤0.01% | 3586 |
|
|
2017
Q4 | $360K | Buy |
15,300
+3,436
| +29% | +$65.3K | ﹤0.01% | 4171 |
|
|
2017
Q3 | $211K | Buy |
+11,864
| New | +$215K | ﹤0.01% | 4380 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Barclays's CRSP Position: Q1 2026 in Review
Barclays reduced its CRISPR Therapeutics (CRSP) stake by 87% in Q1 2026, selling an estimated $11.5M and leaving 32,254 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2515.
Barclays first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $23.2M in Q3 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Barclays held 32,254 shares of CRISPR Therapeutics worth $1.53M as of Q1 2026.
- Barclays sold 217,734 CRISPR Therapeutics shares in Q1 2026, an estimated $11.5M.
- CRISPR Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2515 holding.
- Barclays first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
- Barclays's CRISPR Therapeutics position peaked at $23.2M in Q3 2023.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.